Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology

Arya, A; Silberbauer, J; Teichman, SL; Milner, P; Sulke, N; Camm, AJ (2009) A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. EUROPACE, 11 (4). 458 - 464. ISSN 1099-5129
SGUL Authors: Camm, Alan John

PDF Published Version
Available under License St George's repository terms & conditions.

Download (123kB) | Preview


Aims ATI-2042 (budiodarone) is a chemical analogue of amiodarone with a half life of 7 h. It is electrophysiologically similar to amiodarone, but may not have metabolic and interaction side effects. The sophisticated electrocardiograph logs of advanced DDDRP pacemakers were used to monitor the efficacy of ATI-2042. The aim of this study was to determine the preliminary efficacy and safety of ATI-2042 in patients with paroxsymal atrial fibrillation (PAF) and pacemakers. Methods and results Six women with AF burden (AFB) between 1 and 50% underwent six sequential 2-week study periods. Patients received 200 mg bid of ATI-2042 during Period 2 (p2), 400 mg bid during p3, 600 mg bid during p4, 800 mg bid during p5, and no drug during baseline and washout (p1 and p6). Pacemaker data for the primary outcome measure AFB were downloaded during each period. Mean AFB decreased between baseline and all doses: AFB at baseline (SD) was 20.3 ± 14.6% and mean AFB at 200 mg bid was 5.2 ± 4.2%, at 400 mg bid 5.2 ± 5.2%, at 600 mg bid 2.8 ± 3.4%, and at 800 mg bid 1.5 ± 0.5%. The mean reductions in AFB at all doses of ATI-2042 were statistically significant (P < 0.005). Atrial fibrillation burden increased in washout. Atrial fibrillation episodes tended to increase with ATI-2042, but this was offset by substantial decreases in episode duration. ATI-2042 was generally well tolerated. Conclusion ATI-2042 effectively reduced AFB over all doses studied by reducing mean episode duration. A large-scale study will be required to confirm this effect.

Item Type: Article
Additional Information: Published on behalf of the European Society of Cardiology. All rights reserved. Copyright The Author 2009. For permissions contact the publisher. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact the publisher.
Keywords: Aged, Aged, 80 and over, Amiodarone, Anti-Arrhythmia Agents, Atrial Fibrillation, Benzofurans, Combined Modality Therapy, Dose-Response Relationship, Drug, Electrocardiography, Female, Humans, Middle Aged, Pacemaker, Artificial, Prospective Studies, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, Amiodarone analogue, ATI-2042, Atrial fibrillation, Efficacy, Safety, Pacemakers, Paroxysmal atrial fibrillation, Pacemaker diagnostics, LEFT-VENTRICULAR DYSFUNCTION, MYOCARDIAL-INFARCTION, TEMPORAL PATTERNS, SINUS RHYTHM, AMIODARONE, EFFICACY, TRIAL, DRUG, TACHYCARDIA, DOFETILIDE
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cardiac (INCCCA)
Journal or Publication Title: EUROPACE
ISSN: 1099-5129
Related URLs:
1 April 2009Published
Web of Science ID: WOS:000264652500016
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
Publisher's version:

Actions (login required)

Edit Item Edit Item